Investigational drug · Phase 2
BT02
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Relapsed or Refractory Hematologic Malignancies, Leukemia, Lymphoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 17, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "BT02"
First trial start
2025
Oct 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BT02", any sponsor or status.
Conditions studied
As listed on its trial records.
- Relapsed or Refractory Hematologic Malignancies
- Leukemia
- Lymphoma
- Multiple Myeloma (MM)
Approved drugs for the same conditions: Multiple myeloma · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "BT02" as an intervention, largest first.
- A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic MalignanciesNot yet recruiting
Biotroy TherapeuticsIndustry
NCT07107204 · 116 participants (planned) · Start Oct 2025 · Primary completion Jan 2028
Drug: BT02 · For: Relapsed or Refractory Hematologic Malignancies; Leukemia; Lymphoma and 1 more
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAcademic, hospital or other
NCT06404905 · 60 participants (planned) · Start Jan 24, 2024 · Primary completion Dec 31, 2024
Drug: BT02 monoclonal antibody injection · For: Advanced Solid Tumor
Sites: Beijing, China
- A Clinical Study of BT02 for the Treatment of Patients With Advanced Malignant MelanomaNot yet recruiting
Biotroy TherapeuticsIndustry
NCT07107178 · 58 participants (planned) · Start Aug 8, 2025 · Primary completion May 2027
Drug: BT02 · For: Advanced Melanoma; Advanced Solid Tumor
- A Clinical Study of BT02 in Treating Patients With Advanced Lung CancerNot yet recruiting
Biotroy TherapeuticsIndustry
NCT07110363 · 58 participants (planned) · Start Aug 2025 · Primary completion Mar 2027
Drug: BT02 · For: Advanced Malignant Solid Tumor; Advanced Lung Cancer; Non-Small Cell Lung Cancer and 1 more
Newest research
PubMed records naming it or its code names, newest first.
- Molecular Characterization and Genetic Diversity of Isolated Foot-and-Mouth Disease Viruses Circulating in Cattle in The Mekong Delta Provinces, Vietnam.
Khanh NP, Khang TD, Lam NT, et al. · Vet Med Int 2025
- Monitoring and assessment of the therapeutic impact of metabolites extracted from sponge-associated bacteria screened from Gulf of Mannar, southeast coast of India.
Skariyachan S, Challapilli SB, Packirisamy S, et al. · Environ Monit Assess 2020
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.